European Journal of Cancer
Volume 41, Issue 17 , Pages 2662-2672 , November 2005

Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)

  • Laurence Collette

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC) Data Center – Biostatistics, Avenue E. Mounier 83/11, B-1200, Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 774 16 69; fax: +32 2 771 38 10.
    • ,
  • Hein van Poppel

      Affiliations

    • Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    • ,
  • Michel Bolla

      Affiliations

    • Centre Hospitalier Universitaire de Grenoble–la–Tronche, Grenoble, France
    • ,
  • Paul van Cangh

      Affiliations

    • Department of Urology, Hôpital St. Luc, Brussels, Belgium
    • ,
  • Kris Vekemans

      Affiliations

    • Department of Urology, Virga Jesse Ziekenhuis, Hasselt, Belgium
    • ,
  • Luigi Da Pozzo

      Affiliations

    • Department of Urology, Ospedale San Rafaele, Milano, Italy
    • ,
  • Theo M. de Reijke

      Affiliations

    • Department of Urology, Academisch Medisch Centrum, Amsterdam, The Netherlands
    • ,
  • Antony Verbaeys

      Affiliations

    • Department of Urology, University Hospital, Gent, Belgium
    • ,
  • Jean-François Bosset

      Affiliations

    • Department of Radiation Oncology, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Marianne Piérart

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC) Data Center – Biostatistics, Avenue E. Mounier 83/11, B-1200, Brussels, Belgium
    • ,
  • for the European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups

Received 24 May 2005 ,Accepted 10 June 2005.

References 

  1. Consensus statement: the management of clinically localized prostate cancer. National Institutes of Health Consensus Development Panel. Consensus development conference on the management of clinically localized prostate cancer. NCI Monographs 1988;7:3–6.
  2. Zincke H, Oesterling JE, Blute ML, et al. Long term results after radical prostatectomy for clinically localized prostate cancer. J Urol. 1994;152:1850–1857
  3. Blute ML, Bostwick DG, Bergstrahl EJ, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50:733–739
  4. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997;32:385–390
  5. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  6. Kupelian PA, Katcher J, Levin HS, et al. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiation Oncology Biol Phys. 1997;37:1043–1052
  7. Forman JD. The metamorphosis of a post-prostatectomy patient: from curable to palliative. Urol Oncol. 2004;22:48–49
  8. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866–871
  9. George FW, Carlton CE, Dykhuisen RF, et al. Cobalt-60 telecurietherapy in the definitive treatment of carcinomas of the prostate: a preliminary report. J Urol. 1965;158:515–518
  10. Ray Gr, Cassady JR, Bagshaw MA. External beam megavoltage radiation treatment of post-radical prostatectomy residual or recurrent tumour: Preliminary results. J Urol. 1975;114:98–101
  11. Vanuytsel L, Janssens G, Van Poppel H, et al. Radiotherapy for PSA recurrence after radical prostatectomy. Eur Urol. 2001;39:425–429
  12. Lennemäs B, Edgren M, Häggman M, et al. Postoperative radiotherapy after prostatectomy. A review. Scand J Urol Nephrol. 2003;37:10–15
  13. Bolla M, van Poppel H, Collette L, et al. Post-operative radiotherapy improves clinical and biochemical progression-free survival after radical prostatectomy: first results of EORTC trial 22911. Lancet. 2005;366:572–578
  14. Freedland SJ, Aronson W, Presti JC, et al. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003;169:2142–2146
  15. Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387
  16. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093–2109
  17. Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer, vol. 1: worldwide evidence 1985–1990. Oxford: Oxford University Press; 1990;
  18. Rodrigues G, D’Souza D, Crook J, et al. Contemporary management of prostate cancer: a practice survey of Notario genitourinary radiation oncologists. Radiother Oncol. 2003;69:63–72
  19. Morris SL, Parker C, Huddart R, et al. Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin Oncol (R Coll Radiol). 2004;16:277–282
  20. Valicenti RK, Gomella LG, Perez CA. Radiation therapy after radical prostatectomy: a review of the current issues and options. Semin Radiat Oncol. 2003;13:130–140
  21. D’Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168–172
  22. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  23. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004;171:2255–2259
  24. Graefen M, Karakiewicz PI, Cagiannos I, et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002;7:141–146
  25. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848
  26. Nelson CP, Dunn RL, Wei JT, et al. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urol Oncol. 2003;21:213–218
  27. Freedland SJ, Terris MK, Csathy GS, et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004;171:2215–2220
  28. D’Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18:1164–1172
  29. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169:157–163
  30. Jhaveri FM, Zippe CD, Klein EA, et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54:884–890

PII: S0959-8049(05)00721-5

doi: 10.1016/j.ejca.2005.06.024

European Journal of Cancer
Volume 41, Issue 17 , Pages 2662-2672 , November 2005

Article Tools

* Image Usage & Resolution